- Zomedica has launched a new diagnostics platform aimed at veterinarians looking for ways to rapidly detect pathologies in animals.
- At the same time, it has changed its marketing strategy, by selling directly to customers instead of going through a distributor.
- The market seems not to have digested these two changes coming one after the other, in quick succession.
- Therefore, the stock price has dipped considerably.
- With a good balance sheet, the stock still deserves to be watched closely for ability to sustain revenues in an upbeat market both for animal welfare and point of care (POC).
For further details see:
Zomedica: Should Definitely Be On Your Watchlist